No Data
No Data
Synthetic biology concept stocks opened and fell, and Xinghu Technology hit a fall. Lukang Pharmaceutical, Shuangta Foods, and Weilan Biotech fell by more than 5%, while Fujilai, Hualu Biotech, Yiduoli, and Ruifeng High Materials followed suit.
Synthetic biology concept stocks opened and fell, and Xinghu Technology hit a fall. Lukang Pharmaceutical, Shuangta Foods, and Weilan Biotech fell by more than 5%, while Fujilai, Hualu Biotech, Yiduoli, and Ruifeng High Materials followed suit.
The synthetic biology sector weakened, with Xintiandi falling more than 8%, Fujilai falling nearly 6%, and many stocks such as Lukang Pharmaceutical, Canaan Technology, and Kyodo Pharmaceutical followed suit.
The synthetic biology sector weakened, with Xintiandi falling more than 8%, Fujilai falling nearly 6%, and many stocks such as Lukang Pharmaceutical, Canaan Technology, and Kyodo Pharmaceutical followed suit.
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
Fujilai (301258.SZ): No plans for cellular immunotherapy
Gelonghui, May 10 | Fujilai (301258.SZ) said on the investor interactive platform that the company has no plans for cellular immunotherapy yet.
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
A-share synthetic biology concept shares open 5 consecutive blue biotechnology boards
Glonghui, May 7 | Azure Biotech 5 in a row. Fujilai is close to rising or stopping. Boen Group, Lukang Pharmaceutical, Chuan Ning Biotech, and Borui Pharmaceuticals are opening high.
No Data